Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF FEBRUARY 11, 2021 SAM #7014
SOLICITATION NOTICE

65 -- Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Notice Date

2/9/2021 4:15:29 PM
 

Notice Type

Solicitation
 

NAICS

325412 — Pharmaceutical Preparation Manufacturing
 

Contracting Office

DEFENSE HEALTH AGENCY - AURORA AURORA CO 80011 USA
 

ZIP Code

80011
 

Solicitation Number

HT9402-21-Q-0002
 

Response Due

3/25/2021 10:00:00 AM
 

Archive Date

08/15/2021
 

Point of Contact

Yvette Dluhos
 

E-Mail Address

yvette.h.dluhos.civ@mail.mil
(yvette.h.dluhos.civ@mail.mil)
 

Description

Background: The Department of Defense (DoD) is required by law (10 U.S.C. � 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: May 2021: The following drug classes/sub classes and agents will be reviewed: Menopausal Hormone Therapy, SUB CLASS: Oral Single Agents: Menest and Premarin Menopausal Hormone Therapy, SUB CLASS: Oral Combination Agents: Angeliq; Bijuva; Prefest; Premphase; and Prempro Menopausal Hormone Therapy, SUB CLASS: Vaginal Agents: Estring; Femring; Imvexxy; and Premarin Sleep Disorders, SUB CLASS: Insomnia: Belsomra; Dayvigo; Edluar; Hetlioz; and Zolpimist RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein. The historical utilization data including quantity dispensed and 30 day equivalents by mouth is also attached herein. Pre-Proposal Teleconference: See part 2.4 and 2.5 of the RFQ. The pre-proposal teleconference agenda with dial-in information will be sent out via email after manufacturer R.S.V.P. with the RFQ point of contact. RFQ point of contact: See Part 2.3 of the RFQ. For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD
 

Web Link

SAM.gov Permalink
(https://beta.sam.gov/opp/fa0763fcb428485783cca63ab49871cf/view)
 

Place of Performance

Address: San Antonio, TX 78230, USA

Zip Code: 78230

Country: USA
 

Record

SN05912430-F 20210211/210209230111 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |